The company is founded on a proprietary platform designed to genetically engineer small molecule therapeutics from fungi and plants.
Veteran biotech executives Usman "Oz" Azam, M.D., chief executive officer, and Fred Grossman, D.O., FAPA, Chief Medical officer, lead the company.
Through precision targeting and engineering of the fungal and plant genomes, Empyrean is working to enhance and modulate neuroactive compounds produced by these kingdoms.
The platform is being used to identify therapeutic fungal alkaloids, cannabinoids, and other small molecules that may exhibit enhanced efficacy and safety.
In addition, the platform is designed to discover novel small molecules that may exhibit a therapeutic benefit.
The company's developmental pipeline includes fungal alkaloids, cannabinoids, and other neuroactive compounds, such as N,N-Dimethyltryptamine, for the potential treatment of major depressive disorder, post-traumatic stress disorder, neurologic disorders, substance abuse and dependence, and chronic pain.
Investigational New Drug enabling studies of the company's first genetically engineered encapsulated mushroom drug product are currently underway, and the company aims to enter the clinic for MDD in 2023.
As part of its genetic engineering platform, the company has licensed CRISPR/Cas9 technology from ERS Genomics for genetic engineering applications related to its therapeutic pipeline.
Dr. Azam was previously president and chief executive officer of Tmunity Therapeutics, a biotech developing genetically engineered cell therapies for applications in cancer.
Before Tmunity, he was Global Head of Cell and Gene Therapies at Novartis, where he was responsible for commercial operations, business development licensing, new product commercialization, clinical development, regulatory affairs, and other aspects of the global cell and gene therapies business.
He was chief executive officer of Novaccel Therapeutics, Chief Medical officer of Aspreva Pharmaceuticals, and earlier in his career, held positions at Johnson and Johnson, GSK, and Pfizer.
Dr. Azam received his M.D. from the University of Liverpool School of Medicine and is board certified in obstetrics and gynecology in the United Kingdom.
Before joining Empyrean, Dr. Grossman was Chief Medical officer of Mesoblast Ltd. and president and Chief Medical officer of Glenmark Pharmaceuticals.
He has held executive leadership positions in large pharmaceutical companies, including Eli Lilly, Johnson and Johnson, Bristol Myers Squibb, and Sunovion.
He has been responsible for leading the development, approval, and supporting the launch of numerous global medications addressing significant unmet medical needs across therapeutic areas, particularly in the CNS.
He has held academic appointments and has authored numerous scientific publications. He was trained in psychiatry at Hahnemann University in Philadelphia and at the National Institute of Mental Health in Bethesda, Maryland and completed a Fellowship in the Section on Clinical Pharmacology at the National Institutes of Health. Dr. Grossman is a board-certified psychiatrist and Fellow of the American Psychiatric Association.
Empyrean Neuroscience is a genetic engineering company developing a pipeline of neuroactive therapeutics to treat a range of neuropsychiatric and neurologic disorders.
Through precision genetic modification, transformation, and regeneration of fungi and plants, the platform allows for the creation of small molecule therapeutics.
In addition, the platform enables the discovery of novel small molecules that may exhibit therapeutic properties. The company is based in New York City and Cambridge, UK.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference